pentoxifylline has been researched along with Breast Cancer in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a randomized clinical trial to determine whether the combination of pentoxifylline (PTX) and vitamin E given for 6 months after breast/chest wall irradiation effectively prevents radiation-induced fibrosis (RIF)." | 9.17 | Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. ( Bhatia, S; Bodeker, K; Buatti, J; Button, AM; Jacobson, G; Smith, BJ, 2013) |
| " Women with breast cancer were treated for 12 months with 400 mg pentoxifylline t." | 9.14 | Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5). ( Höglund, P; Johansson, K; Jönsson, C; Killander, F; Kjellén, E; Magnusson, M; Malmström, P; Weddig, A, 2009) |
| " A number of studies testing alpha-tocopherol (vitamin E) and pentoxifylline suggest evidence of clinical regression of superficial radiation-induced fibrosis but there is only very limited evidence from randomised trials." | 9.11 | Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. ( Cornes, P; Earl, J; Gothard, L; Hall, E; MacLaren, J; Mortimer, P; Peacock, J; Peckitt, C; Woods, M; Yarnold, J, 2004) |
| " This study was conducted to determine whether oral and intravenous (IV) PTX and Cipro permits increased dose levels of oral busulfan (BU) with a fixed dose of IV cyclophosphamide (CY) in patients with breast cancer receiving autologous or syngeneic hematopoetic cell transplantation." | 9.11 | Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants. ( Bensinger, WI; Buckner, CD; Holmberg, L; Lilleby, K; Slattery, JT; Storb, R, 2004) |
| "Intrinsic estrogenicities of the selective estrogen receptor modulators (SERMs) toremifene 60 mg daily or 200 mg daily and tamoxifen 20 mg daily (TOR60, TOR200 and TAM20) were compared in a randomized clinical study in postmenopausal women with advanced breast cancer." | 9.10 | Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. ( Ellmén, J; Hakulinen, P; Hayes, DF; Partanen, A, 2003) |
| "The data indicate a beneficial therapeutic effect of pentoxifylline and vitamin E on radiation-induced fibrosis." | 8.79 | [The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report]. ( Gottlöber, P; Korting, HC; Krähn, G; Peter, RU; Stock, W, 1996) |
| " As per the reports, the choice of drug in the treatment of breast cancer is paclitaxel, but the major limitation is its toxicity." | 7.77 | Unravelling the antimetastatic potential of pentoxifylline, a methylxanthine derivative in human MDA-MB-231 breast cancer cells. ( Goel, PN; Gude, RP, 2011) |
| "Radiation-induced fibrosis is a side effect of radiation therapy and may occur in up to 13% of the cases in patients (Radiother Oncol, 2009;90:80), fortunately usually is modest/localized and not associated with marked symptoms." | 6.58 | Pentoxifylline and vitamin E for treatment or prevention of radiation-induced fibrosis in patients with breast cancer. ( Jones, EL; Kaidar-Person, O; Marks, LB, 2018) |
| "Pentoxifylline (PTX) is a methylxanthine derivative that improves blood flow by decreasing its viscosity." | 5.40 | Pentoxifylline regulates the cellular adhesion and its allied receptors to extracellular matrix components in breast cancer cells. ( Goel, PN; Gude, RP, 2014) |
| "Pentoxifylline (PTX) is a methylxanthine derivative currently being used in the treatment of peripheral vascular diseases." | 5.39 | Curbing the focal adhesion kinase and its associated signaling events by pentoxifylline in MDA-MB-231 human breast cancer cells. ( Goel, PN; Gude, RP, 2013) |
| "To conduct a randomized clinical trial to determine whether the combination of pentoxifylline (PTX) and vitamin E given for 6 months after breast/chest wall irradiation effectively prevents radiation-induced fibrosis (RIF)." | 5.17 | Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. ( Bhatia, S; Bodeker, K; Buatti, J; Button, AM; Jacobson, G; Smith, BJ, 2013) |
| " Women with breast cancer were treated for 12 months with 400 mg pentoxifylline t." | 5.14 | Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5). ( Höglund, P; Johansson, K; Jönsson, C; Killander, F; Kjellén, E; Magnusson, M; Malmström, P; Weddig, A, 2009) |
| " A number of studies testing alpha-tocopherol (vitamin E) and pentoxifylline suggest evidence of clinical regression of superficial radiation-induced fibrosis but there is only very limited evidence from randomised trials." | 5.11 | Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. ( Cornes, P; Earl, J; Gothard, L; Hall, E; MacLaren, J; Mortimer, P; Peacock, J; Peckitt, C; Woods, M; Yarnold, J, 2004) |
| " This study was conducted to determine whether oral and intravenous (IV) PTX and Cipro permits increased dose levels of oral busulfan (BU) with a fixed dose of IV cyclophosphamide (CY) in patients with breast cancer receiving autologous or syngeneic hematopoetic cell transplantation." | 5.11 | Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants. ( Bensinger, WI; Buckner, CD; Holmberg, L; Lilleby, K; Slattery, JT; Storb, R, 2004) |
| "Intrinsic estrogenicities of the selective estrogen receptor modulators (SERMs) toremifene 60 mg daily or 200 mg daily and tamoxifen 20 mg daily (TOR60, TOR200 and TAM20) were compared in a randomized clinical study in postmenopausal women with advanced breast cancer." | 5.10 | Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. ( Ellmén, J; Hakulinen, P; Hayes, DF; Partanen, A, 2003) |
| "The data indicate a beneficial therapeutic effect of pentoxifylline and vitamin E on radiation-induced fibrosis." | 4.79 | [The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report]. ( Gottlöber, P; Korting, HC; Krähn, G; Peter, RU; Stock, W, 1996) |
| " As per the reports, the choice of drug in the treatment of breast cancer is paclitaxel, but the major limitation is its toxicity." | 3.77 | Unravelling the antimetastatic potential of pentoxifylline, a methylxanthine derivative in human MDA-MB-231 breast cancer cells. ( Goel, PN; Gude, RP, 2011) |
| " We recommend the prophylactic use of Ptx, finding it to be safe and effective." | 2.71 | Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. ( Atavci, S; Egehan, I; Kitapci, M; Ozturk, B, 2004) |
| "Radiation-induced fibrosis is a side effect of radiation therapy and may occur in up to 13% of the cases in patients (Radiother Oncol, 2009;90:80), fortunately usually is modest/localized and not associated with marked symptoms." | 2.58 | Pentoxifylline and vitamin E for treatment or prevention of radiation-induced fibrosis in patients with breast cancer. ( Jones, EL; Kaidar-Person, O; Marks, LB, 2018) |
| "Breast cancer was the most predominant neoplasm (70." | 1.91 | Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series. ( da Motta Silveira, FM; de Andrade Veras, SR; de Lima E Silva, DF; de Mello, MJG; Magalhães, JMI; Regueira, LS, 2023) |
| "Pentoxifylline (PTX) is a methylxanthine derivative that improves blood flow by decreasing its viscosity." | 1.40 | Pentoxifylline regulates the cellular adhesion and its allied receptors to extracellular matrix components in breast cancer cells. ( Goel, PN; Gude, RP, 2014) |
| "Pentoxifylline (PTX) is a methylxanthine derivative currently being used in the treatment of peripheral vascular diseases." | 1.39 | Curbing the focal adhesion kinase and its associated signaling events by pentoxifylline in MDA-MB-231 human breast cancer cells. ( Goel, PN; Gude, RP, 2013) |
| "The diagnosis was made as right breast cancer (T4c, N3c, M1, and stage IV)." | 1.35 | [A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies]. ( Aoyagi, H; Hamada, S; Kaneko, J; Katsuta, E; Maejima, S; Makinose, T; Okubo, K; Saguchi, M; Sato, T; Sekine, T; Someno, Y; Sugihara, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (23.08) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Magalhães, JMI | 1 |
| da Motta Silveira, FM | 1 |
| Regueira, LS | 1 |
| de Lima E Silva, DF | 1 |
| de Andrade Veras, SR | 1 |
| de Mello, MJG | 1 |
| Kaidar-Person, O | 1 |
| Marks, LB | 1 |
| Jones, EL | 1 |
| Goel, PN | 3 |
| Gude, RP | 3 |
| Nidhyanandan, S | 1 |
| Boreddy, TS | 1 |
| Chandrasekhar, KB | 1 |
| Reddy, ND | 1 |
| Kulkarni, NM | 1 |
| Narayanan, S | 1 |
| Cook, M | 1 |
| Johnson, N | 1 |
| Zegzula, HD | 1 |
| Schray, M | 1 |
| Glissmeyer, M | 1 |
| Sorenson, L | 1 |
| Magnusson, M | 1 |
| Höglund, P | 1 |
| Johansson, K | 1 |
| Jönsson, C | 1 |
| Killander, F | 1 |
| Malmström, P | 1 |
| Weddig, A | 1 |
| Kjellén, E | 1 |
| Aoyagi, H | 1 |
| Kaneko, J | 1 |
| Makinose, T | 1 |
| Someno, Y | 1 |
| Katsuta, E | 1 |
| Saguchi, M | 1 |
| Okubo, K | 1 |
| Hamada, S | 1 |
| Sekine, T | 1 |
| Sato, T | 1 |
| Sugihara, K | 1 |
| Maejima, S | 1 |
| Shoma, A | 1 |
| Eldars, W | 1 |
| Noman, N | 1 |
| Saad, M | 1 |
| Elzahaf, E | 1 |
| Abdalla, M | 1 |
| Eldin, DS | 1 |
| Zayed, D | 1 |
| Shalaby, A | 1 |
| Malek, HA | 1 |
| Szabolcsi, O | 1 |
| Nagy-Toldi, A | 1 |
| Zeher, M | 1 |
| Végh, J | 1 |
| Jacobson, G | 1 |
| Bhatia, S | 1 |
| Smith, BJ | 1 |
| Button, AM | 1 |
| Bodeker, K | 1 |
| Buatti, J | 1 |
| Delanian, S | 4 |
| Porcher, R | 2 |
| Balla-Mekias, S | 2 |
| Lefaix, JL | 4 |
| Ellmén, J | 1 |
| Hakulinen, P | 1 |
| Partanen, A | 1 |
| Hayes, DF | 1 |
| Ozturk, B | 1 |
| Egehan, I | 1 |
| Atavci, S | 1 |
| Kitapci, M | 1 |
| Gothard, L | 1 |
| Cornes, P | 1 |
| Earl, J | 1 |
| Hall, E | 1 |
| MacLaren, J | 1 |
| Mortimer, P | 1 |
| Peacock, J | 1 |
| Peckitt, C | 1 |
| Woods, M | 1 |
| Yarnold, J | 1 |
| Bensinger, WI | 1 |
| Buckner, CD | 1 |
| Lilleby, K | 1 |
| Holmberg, L | 1 |
| Storb, R | 1 |
| Slattery, JT | 1 |
| Anscher, MS | 1 |
| Rudant, J | 1 |
| Fan, S | 1 |
| Smith, ML | 1 |
| Rivet, DJ | 1 |
| Duba, D | 1 |
| Zhan, Q | 1 |
| Kohn, KW | 1 |
| Fornace, AJ | 1 |
| O'Connor, PM | 1 |
| Stewart, DJ | 1 |
| Evans, WK | 1 |
| Logan, D | 1 |
| Gottlöber, P | 1 |
| Krähn, G | 1 |
| Korting, HC | 1 |
| Stock, W | 1 |
| Peter, RU | 1 |
| Steeves, RA | 1 |
| Robins, HI | 1 |
| Dezube, BJ | 1 |
| Fridovich-Keil, JL | 1 |
| Bouvard, I | 1 |
| Lange, RF | 1 |
| Pardee, AB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| Evaluation of the Medical Benefit of a Spa Therapy on the Evolutionary Genius of Late Sequelae Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission[NCT05874492] | 110 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | |||
| Development of Radiation Fibrosis in Patients Treated With Pentoxyphylline and Vitamin E: a Prospective Randomized Study[NCT00583700] | Phase 2 | 54 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.[NCT00893035] | 885 participants (Actual) | Observational | 2006-06-30 | Completed | |||
| Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy[NCT00969111] | 70 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | |||
| An Expanded Phase II Study of Hypofractionated Dose Intense Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate[NCT01368055] | 361 participants (Actual) | Interventional | 2011-09-30 | Active, not recruiting | |||
| Double-Blind, Placebo-Controlled, Randomised Trial Of Alpha-Tocopherol And Oxpentifylline In Patients With Radiation Fibrosis[NCT00022204] | Phase 2 | 0 participants | Interventional | 2000-01-31 | Completed | ||
| Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment[NCT03040778] | Phase 3 | 100 participants (Anticipated) | Interventional | 2018-04-01 | Enrolling by invitation | ||
| Normal Tissue Oxygenation Following Radiotherapy[NCT00677040] | 20 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A primary outcome of interest is the composite Subjective, Objective, Management, and Analytic (SOMA) score at 18-month follow-up visit. Maximum score is 45, with a score of 0 being ideal and representing no treatment-related side effects at the study visit. (NCT00583700)
Timeframe: 18 month post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Control Arm | 1.59 |
| Intervention: Pentoxifylline & Vitamin E | 1.0 |
"Tissue compliance meter measurements of the treated breast compared to the non-treated breast were obtained at 18 months post-radiation therapy. Tissue compliance simply means how soft and pliable the breast tissue is when force is applied to it.~One physician would hold the tissue compliance meter (TCM) against the participant's skin. A standard amount of force would be applied. A second physician would read the displacement scale for a specific set of areas on the breast. The range of the scale was 0 to 60 milimeters (mm). The physician's were blineded to the participant's intervention at the time of measurement.~The final value is the difference between the untreated and the treated breast [untreated - treated]. The range of these differences was -3.3 to 7.0 mm." (NCT00583700)
Timeframe: 18 months post-treatment
| Intervention | milimeters (mm) (Mean) |
|---|---|
| Control Arm | 2.10 |
| Intervention: Pentoxifylline & Vitamin E | 0.88 |
Transcutaneous oxygen detector is used to measure the partial pressure of oxygen. The unit detects electrolytes ionized by oxygen. The measuring electrode also heats the skin being measured to facilitate maximal bloodflow to the area. (NCT00677040)
Timeframe: One visit for 20 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Subjects | 62.5 |
(NCT00677040)
Timeframe: One visit
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| late subcutaneous toxicitiy score 1 | late subcutaneous toxcity score 2 | late skin toxicity score 1 | late skin toxicity score 2 | |
| Subjects | 19 | 1 | 19 | 1 |
2 reviews available for pentoxifylline and Breast Cancer
| Article | Year |
|---|---|
Pentoxifylline and vitamin E for treatment or prevention of radiation-induced fibrosis in patients with breast cancer.
Topics: Breast Neoplasms; Female; Fibrosis; Humans; Pentoxifylline; Radiation Injuries; Radiation-Protective | 2018 |
[The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report].
Topics: Breast Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Therapy, Combination; Fe | 1996 |
9 trials available for pentoxifylline and Breast Cancer
| Article | Year |
|---|---|
Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5).
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Humans | 2009 |
Pentoxifylline and local honey for radiation-induced burn following breast conservative surgery.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Honey; Humans; Mastectomy, Segment | 2010 |
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Compliance; Drug Therapy, Combination; Fem | 2013 |
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Compliance; Drug Therapy, Combination; Fem | 2013 |
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Compliance; Drug Therapy, Combination; Fem | 2013 |
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Compliance; Drug Therapy, Combination; Fem | 2013 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
Topics: Aged; Antioxidants; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Pentoxifylli | 2003 |
Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Antithrombin | 2003 |
Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial.
Topics: Adult; Breast Neoplasms; Female; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Pentoxify | 2004 |
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Confid | 2004 |
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Confid | 2004 |
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Confid | 2004 |
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Confid | 2004 |
Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants.
Topics: Adult; Anti-Infective Agents; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Ciprofloxacin | 2004 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combina | 2005 |
15 other studies available for pentoxifylline and Breast Cancer
| Article | Year |
|---|---|
Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series.
Topics: Adolescent; Adult; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservati | 2023 |
Curbing the focal adhesion kinase and its associated signaling events by pentoxifylline in MDA-MB-231 human breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Fe | 2013 |
Pentoxifylline regulates the cellular adhesion and its allied receptors to extracellular matrix components in breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Chick Embryo; Chickens; Chorioallantoic | 2014 |
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzami | 2015 |
Prophylactic use of pentoxifylline (Trental) and vitamin E to prevent capsular contracture after implant reconstruction in patients requiring adjuvant radiation.
Topics: Adult; Breast Implantation; Breast Implants; Breast Neoplasms; Cohort Studies; Drug Therapy, Combina | 2016 |
[A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2009 |
Unravelling the antimetastatic potential of pentoxifylline, a methylxanthine derivative in human MDA-MB-231 breast cancer cells.
Topics: Acridine Orange; Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Move | 2011 |
[Systemic sclerosis in a patient suffering from breast cancer].
Topics: Adult; Amlodipine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Duct | 2012 |
The irreversibility of radiation-induced fibrosis: fact or folklore?
Topics: Antioxidants; Brachytherapy; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Pentoxifyl | 2005 |
Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
Topics: Apoptosis; Breast Neoplasms; Cell Line; Cell Survival; Cisplatin; Clone Cells; Doxorubicin; Etoposid | 1995 |
Addition of pentoxifylline plus nifedipine to chemotherapy in patients with cisplatin-resistant cancers of the lung and other sites.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Evaluation; Drug R | 1994 |
Pentoxifylline treatment of radiation mastitis.
Topics: Breast Neoplasms; Female; Humans; Mastitis; Pentoxifylline; Radiation-Protective Agents; Radiodermat | 1998 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate.
Topics: Aged; Antimetabolites; Antioxidants; Breast Neoplasms; Clodronic Acid; Drug Therapy, Combination; Fe | 2002 |
Pentoxifylline and wellbeing in patients with cancer.
Topics: Adult; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplas | 1990 |